Atherosclerosis and inflammation: therapeutic targets and ways of correction

Atherosclerosis and inflammation: therapeutic targets and ways of correction

Atherosclerosis is a chronic inflammatory vascular disease caused by various risk factors, in particular smoking, obesity, high blood pressure, and dyslipidemia. In addition, such signaling pathways as NLRP3 inflammasome, toll-like receptors, proprotein convertase subtilisin/kexin type 9, Notch and...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. A. Klimenko, D. Yu. Andriyashkina, K. I. Ogarkova
Format:	Article
Language:	Russian
Published:	ABV-press 2024-06-01
Series:	Klinicist
Subjects:	atherosclerosis low-density lipoproteins cholesterol inflammation vascular cells immune cells signaling pathways nlrp3 inflammasome proprotein convertase subtilisin/kexin type 9 notch pathway wnt pathway lipidlowering drugs
Online Access:	https://klinitsist.abvpress.ru/Klin/article/view/587
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
by: Xiaocui Chen, et al.
Published: (2025-03-01)

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

PCSK9 promotes T helper 1 and T helper 17 cell differentiation by activating the nuclear factor‐κB pathway in ankylosing spondylitis
by: Jianfei Cai, et al.
Published: (2023-05-01)

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
by: Antonio J. Vallejo‐Vaz, et al.
Published: (2018-09-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection
by: Omer Qutaiba B. Allela, et al.
Published: (2024-12-01)

Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9
by: Marcella Palumbo, et al.
Published: (2025-03-01)

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors
by: Je-Wen Liou, et al.
Published: (2024-09-01)

Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease
by: Haixia Tang, et al.
Published: (2025-08-01)

PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics
by: Yu. A. Drenina, et al.
Published: (2020-09-01)

Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
by: Gregory P. Geba, et al.
Published: (2024-12-01)

MicroRNA-1912 regulates cholesterol homeostasis by targeting PCSK9
by: Chan Joo Lee, et al.
Published: (2025-09-01)

Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects
by: Ajoy Basak
Published: (2025-03-01)

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
by: Zhenzhen Li, et al.
Published: (2024-11-01)

Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia
by: Hongyan Jiang, et al.
Published: (2024-12-01)

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
by: Natalie Schellack, et al.
Published: (2016-01-01)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01)

Human PCSK9D374Y exacerbates methionine choline deficiency diet-induced nonalcoholic steatohepatitis in mice
by: Abidan·ABUDURUSULI, CHEN Xiaocui, CUI Yuanfeng, Tuoluonayi·MIJITI, DENG Lihui, CHEN Bangdang
Published: (2025-05-01)

Association of Insomnia, Lipid Profile, and Lipid-Lowering Medications: A Narrative Review
by: Fang Jia, et al.
Published: (2025-01-01)

Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention
by: Michelangelo Rottura, et al.
Published: (2025-03-01)

Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study)
by: M. V. Ezhov, et al.
Published: (2023-05-01)

Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus
by: Zhicai Feng, et al.
Published: (2023-12-01)

EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020)
by: V. V. Kukharchuk, et al.
Published: (2020-06-01)

Inclisiran for the treatment of hypercholesterolaemia
by: Joel C Marrs, et al.
Published: (2024-11-01)

Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
by: Xi Li, et al.
Published: (2025-02-01)

Exploring the therapeutic potential of precision medicine in rare genetic obesity disorders: a scientific perspective
by: Tinh-Hai Collet, et al.
Published: (2024-12-01)

Subtilisin/kexin type 9 protein convertase and interleukin 1 beta alterations in acute myocardial infarction
by: Michał Majewski, et al.
Published: (2025-05-01)

Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis
by: Yumin Zhang, et al.
Published: (2025-02-01)

Modified Diagnostic Criteria Tools for Familial Hypercholesterolemia without the Requirement for Clinical Genetic Testing: Rationale and Design of the MOOCS Adaptive Clinical Trial
by: Satyanarayana Upadhyayula
Published: (2024-10-01)

Kukoamine B regulates pyroptosis mediated by NLRP3/Caspase-1/GSDMD pathway to alleviate lipopolysaccharide-induced macrophage inflammation
by: NING Pu, et al.
Published: (2024-07-01)

Chaperonin containing TCP1 subunit 6A may activate Notch and Wnt pathways to facilitate the malignant behaviors and cancer stemness in oral squamous cell carcinoma
by: Yangyi Chen, et al.
Published: (2024-12-01)

Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer
by: Aviv Philip Goncharov, et al.
Published: (2025-12-01)

Complex immunotoxic effects of T-2 Toxin on the murine spleen and thymus: Oxidative damage, inflammasomes, apoptosis, and immunosuppression
by: Mingyan Chen, et al.
Published: (2025-01-01)

Notch2 improves granulosa cell functions in premature ovarian failure by activating the Wnt2/β-catenin pathway
by: Xia Liang, et al.
Published: (2025-07-01)

Atherosclerosis and inflammation – the path from pathogenesis to treatment: review of the current state of the issue (part 2)
by: A. A. Avagimyan, et al.
Published: (2025-07-01)

Flavonoid GL-V9 suppresses development of human hepatocellular cancer cells by inhibiting Wnt/β-Cantenin signaling pathway
by: Ye Gu, et al.
Published: (2025-04-01)

Tumor stem cells from glioblastoma multiforme
by: Z. N. Nikiforova, et al.
Published: (2016-06-01)

ACT001 improves OVX-induced osteoporosis by suppressing the NF-κB/NLRP3 signaling pathway
by: Yuan Li, et al.
Published: (2025-04-01)

Mechanism of Resveratrol on LPS/ATP-induced pyroptosis and inflammatory response in HT29 cells
by: Peizhuang Zhao, et al.
Published: (2024-12-01)